The estimated Net Worth of Jennifer E. Cook is at least 2.75 百万$ dollars as of 6 June 2024. Ms. Cook owns over 1,458 units of BridgeBio Pharma Inc stock worth over 560,864$ and over the last 6 years she sold BBIO stock worth over 534,299$. In addition, she makes 1,656,040$ as Independent Director at BridgeBio Pharma Inc.
Jennifer has made over 9 trades of the BridgeBio Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 1,458 units of BBIO stock worth 31,682$ on 6 June 2024.
The largest trade she's ever made was exercising 3,576 units of BridgeBio Pharma Inc stock on 16 November 2021 worth over 100,092$. On average, Jennifer trades about 618 units every 52 days since 2018. As of 6 June 2024 she still owns at least 20,038 units of BridgeBio Pharma Inc stock.
You can see the complete history of Ms. Cook stock trades at the bottom of the page.
Jennifer E. Cook serves as Independent Director of the Company. She is currently the owner and principal of Jennifer Cook Consulting since July 2019. Ms. Cook has served as a member of the board of directors of Denali Therapeutics, Inc. (Nasdaq: DNLI) since November 2018. Ms. Cook served as the Chief Executive Officer of GRAIL from January 2018 to June 2019. Previously, Ms. Cook was at Roche Pharmaceuticals and Genentech, where she held a number of senior management positions; from January 2017 to December 2017, Ms. Cook served as Senior Vice President, Global Head of Clinical Operations for Roche Pharmaceuticals; from September 2013 to December 2016, Ms. Cook served as Head of Region Europe Pharma for Roche Pharmaceuticals; and from July 2010 to September 2013, Ms. Cook served as the Senior Vice President, Business Unit Head Immunology and Ophthalmology for Genentech. Ms. Cook holds a B.A. in human biology and an M.S. in biology from Stanford University, as well as an M.B.A. from the Haas School of Business at University of California, Berkeley. Ms. Cook’s qualifications to serve on our Board of Directors include her extensive experience as a senior management executive of healthcare and biotechnology companies, including as the senior vice president of one of the world’s largest healthcare companies.
As the Independent Director of BridgeBio Pharma Inc, the total compensation of Jennifer Cook at BridgeBio Pharma Inc is 1,656,040$. There are 6 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of 26,334,100$.
Jennifer Cook is 54, she's been the Independent Director of BridgeBio Pharma Inc since 2019. There are 11 older and 11 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
Jennifer's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over 409,396,563$ worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth 209,241,115$ . The most active insiders traders include Global Investors Lp Viking ...、Andrew Lo、Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of 4,173,197$. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth 1,554,481$.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: